SCHEMBL10150388

SCHEMBL10150388

Cc1cc(C)c2c(c1Cl)CC(=O)/C=C/CC/C=C/[C@H](C)[C@@H](C)OC2=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 4/20 0.49
HSP90AA1 P07900 2/20 0.37
MAPT P10636 2/20 0.37
GAA P10253 1/20 0.37
RAB9A P51151 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
NLRP3 Q96P20 1/20 0.37
CBR1 P16152 1/20 0.37
PTGS2 P35354 1/20 0.37
ACLY P53396 1/20 0.37
FTO Q9C0B1 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37
F13A1 P00488 1/20 0.36
TGM2 P21980 1/20 0.36
MAOA P21397 4/20 0.34
VCP P55072 1/20 0.34
MAP2K1 Q02750 6/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19418072 0.90 HSP90AB1 (0.60) HSP90AB1HSP90AA1MAPTGAARAB9A
SCHEMBL10150389 0.83 HSP90AB1 (0.71) HSP90AB1HSP90AA1MAPTGAARAB9A
SCHEMBL10150178 0.83 HSP90AB1 (0.71) HSP90AB1HSP90AA1MAPTGAARAB9A
SCHEMBL10150157 0.83 HSP90AB1 (0.71) HSP90AB1HSP90AA1MAPTGAARAB9A
SCHEMBL10150395 0.79 HSP90AB1 (0.34) HSP90AB1MAOAMAP2K1
SCHEMBL10150155 0.79 HSP90AB1 (0.53) HSP90AB1HSP90AA1MAPTGAARAB9A
SCHEMBL10150392 0.79 HSP90AB1 (0.32) HSP90AB1RAB9A
SCHEMBL10150827 0.77 HSP90AB1 (0.46) HSP90AB1F13A1TGM2MAOAVCP
SCHEMBL10150899 0.77 HSP90AB1 (0.55) HSP90AB1HSP90AA1MAPTGAARAB9A
SCHEMBL10150383 0.76 HSP90AB1 (0.73) HSP90AB1HSP90AA1MAPTGAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450305-B2 Macrocyclic compounds useful as inhibitors of kinases and HSP90 UNIVERSITE DE STRASBOURG (FR) 2013-05-28 US disclosed
US-8329683-B2 Treatment of neurofibromatosis with radicicol and its derivatives NEXGENIX PHARMACEUTICALS, LLC (US) 2012-12-11 US disclosed
US-20120077775-A1 MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-03-29 US disclosed
US-8067412-B2 analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen UNIVERSITE DE STRASBOURG (FR) 2011-11-29 US disclosed
US-20100292218-A1 Treatment Of Neurofibromatosis With Radicicol And Its Derivatives NEXGENIX PHARMACEUTICALS HOLDINGS, INC. 2010-11-18 US disclosed
US-20080146545-A1 Macrocyclic compounds useful as inhibitors of kinases and HSP90 UNIVERSITE DE STRASBOURG (FR) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077775-A1 MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 HSP90AB1, HSP90AA1, HSP90AB2P HSP90AB1 1/4885HSP90AA1 2/4885MAPT 1982/4885
US-20100292218-A1 Treatment Of Neurofibromatosis With Radicicol And Its Derivatives HSP90AB2P, HSP90AA1, HSPA2 HSP90AB1 4/4885HSP90AA1 2/4885MAPT 2339/4885
US-20080146545-A1 Macrocyclic compounds useful as inhibitors of kinases and HSP90 HSP90AB1, HSP90AA1, HSP90AB2P HSP90AB1 1/4885HSP90AA1 2/4885MAPT 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.